Quarterly ResultJul 29, 2026, 07:02 AM
Teva Q2 Revenue $4.1B; Innovative Brands Up 43%; Raises Outlook for Key Products
AI Summary
Teva Pharmaceutical Industries Ltd. reported Q2 2026 revenues of $4.1 billion, a 1% decrease year-over-year, primarily due to lower generics sales. However, its key innovative brands collectively grew 43% in local currency to over $1 billion, leading the company to raise its 2026 outlook for these brands to approximately $3.7 billion. The quarter saw a GAAP loss per share of $0.49, largely due to the $700 million acquisition of Emalex Biosciences and its asset ecopipam, while non-GAAP diluted EPS was $0.02. Teva also announced the replacement of its ADS program with a direct NYSE listing of ordinary shares.
Key Highlights
- Q2 2026 revenues were $4.1 billion, a 1% decrease year-over-year in U.S. dollars.
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% year-over-year in local currency to over $1 billion.
- Raised 2026 revenue outlook for key innovative brands to ~$3.7 billion combined.
- GAAP loss per share was $0.49, including $726 million expenses from Emalex acquisition.
- Non-GAAP diluted EPS was $0.02, impacted by ($0.61) per share from Emalex acquisition.
- Acquired Emalex Biosciences for ~$700 million and submitted NDA for ecopipam.
- Launched AHZANTIVE® biosimilar in Europe and signed Polpharma Biologics agreement.
- Announced replacement of ADS program with direct NYSE listing of ordinary shares.
Price Impact
More from TEVA